Early patients with trigeminal neuralgia are often treated with medication (carbamazepine), which can be controlled in 70% of patients. However, as the disease progresses, the sensitivity of the medication becomes less and less effective in relieving pain. In the late stage of the disease, it is often necessary to increase the amount of medication to work, and even the maximum amount may not work, and it can also cause damage to liver and kidney function. The biggest advantage of drug therapy is that it is easy to take and can only control the disease in the early stage. However, as the disease progresses, the amount of medication is not effective. If the course of the disease is recurrent, surgical treatment, known as microvascular decompression, is required. This procedure completely preserves the normal sensory and motor conduction functions of the nerve. Most of the causes of trigeminal neuralgia are caused by the compression of the trigeminal nerve root by the surrounding blood vessels, so microvascular decompression is adopted to find the blood vessels compressing the nerve root under the guidance of microscope and isolate them by inserting Teflon spacers between the blood vessels and the nerve, and the facial pain will disappear immediately and restore health after eliminating the cause from the root of the disease, and no brain tissue or nerve will be damaged. Microvascular decompression has become a scientific method for clinical treatment of trigeminal neuralgia, and the procedure is safe and effective.